ArticleThe Journal of clinical endocrinology and metabolism2025
Brief, Low-impact, High-intensity Osteogenic Loading in Postmenopausal Osteoporosis: A Quasi-experimental Case-series Study.
Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The effect of OsteoStrong compared to dynamic multicomponent exercise on bone strength in older women: the BONEMORE non-inferiority randomized controlled trial.Archives of osteoporosis · 2026Trial
- Article
- The STROBE guidelines and the Αristotelian mesotes curve.Hormones (Athens, Greece) · 2026Article
- Brief, Low-impact, High-intensity Osteogenic Loading in Postmenopausal Osteoporosis: A Quasi-experimental Case-series Study.The Journal of clinical endocrinology and metabolism · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
backgroundOsteoporosis is characterized by reduced bone mineral density (BMD) and disrupted microarchitecture estimated by trabecular bone score (TBS). Osteostrong® is a bone-strengthening system implementing 4 devices and incorporating brief (10-minute), weekly, low-impact, high-intensity osteogenic loading exercises. The aim of this study was to assess changes in BMD and TBS in the lumbar spine and/or hip over 12 months in peri-/post menopausal women with Osteoporosis following Osteostrong® intervention and to compare these outcomes with women who did not receive such intervention. METHODS AND SUBJECTS: A quasi-experimental case-series study in which 147 participants were separated into 2 groups, following informed consent: 75 in group A receiving Osteostrong® (subgroup G1 without and G2 with antiresorptive medication); and 72 in group B without Osteostrong® (subgroup G3 without and G4 with antiresorptive medication). Changes in lumbar spine and hip BMD and/or TBS were assessed at inclusion and 12 months later. Bonferroni-adjusted non-parametric paired tests examined for significant paired mean differences within each subgroup.
resultsAfter Bonferroni adjustment, significant increases were observed in lumbar spine BMD in G2 (mean paired change: 0.029 g/cm2; Bonferroni-adjusted p < 0.001), and G4 (mean paired change: 0.025 g/cm2; Bonferroni-adjusted p = 0.05) as well as BMD-total hip left in G2 (mean paired change: 0.028 g/cm2; Bonferroni-adjusted p = 0.05). Other within-group changes in femoral neck BMD, total hip BMD, and TBS did not retain significance following Bonferroni correction.
conclusionThe Osteostrong® intervention showed modest lumbar spine BMD improvements over 12 months; some subgroup effects were significant but not when Bonferroni-adjusted, warranting cautious interpretation and further randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.